Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia

Meaney, Anna Maria, Smith, Shubulade, Howes, O. D., O'Brien, Moira, Murray, Robin M., O'Keane, Veronica·2004·British Journal of Psychiatry
DOI 10.1192/bjp.184.6.503

Cited by (217)

Items 101–200 of 217

  1. Prevalence of osteopenia and osteoporosis and factors associated with decreased bone mineral density in elderly inpatients with psychiatric disorders in Huzhou, China.
    Ping Guo, Shikai Wang, Yiping Zhu, Xinhua Shen, Jin Xue-min, Mincai Qian, Hongyu Tang · 2012 · PubMed Central
  2. Bone mineral density as a marker of cumulative endogenous estrogen exposure: Relationship to background genetic risk of psychotic disorder
    Christine van der Leeuw, Petra Habets, Patrick A.E. Domen, Marinus J.P.G. van Kroonenburgh, Jim van Os, Machteld C. Marcelis · 2012 · Schizophrenia Research
  3. Association of mental disorders and psychotropic medications with bone texture as measured with trabecular bone score
    Sina Hafizi, Lisa Marie Lix, Didier B. Hans, James M. Bolton, William Donald Leslie · 2022 · Bone
  4. Metabolic and Cardiac Side Effects of Second-generation Antipsychotics: What Every Clinician Should Know
    Ericka L. Breden Crouse, Mei T. Liu, Stacey R. Dean, Toyin S. Tofade · 2009 · Journal of Pharmacy Practice
  5. Effect of risperidone on proliferation and apoptosis of MC3T3-E1 cells
    Lei Zheng, Lixia Yang, Xin Zhao, Niya Long, Peifan Li, Yiming Wang · 2019 · Brazilian Journal of Medical and Biological Research
  6. The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients
    Chikako Ohta, Norio Yasui‐Furukori, Hanako Furukori, Shoko Tsuchimine, Manabu Saito, Taku Nakagami, Kaori Yoshizawa, Sunao Kaneko · 2011 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  7. The Effects of Chlorpromazine on Reproductive System and Function in Female Rats.
    Zahra Zamani, Samad Zare, Rajabali Sadrkhanlou, Abbas Ahmadi, Elham Movahed · 2015 · PubMed Central
  8. The central mechanism of risperidone-induced hyperprolactinemia
    Weiwei Sun, Linyu Li, Xu‐Feng Huang, Yan‐Chuan Shi, He-qin Yang, Zhi-yuan Song, Shu Lin · 2017 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  9. Improving blood and ECG monitoring among patients prescribed regular antipsychotic medications.
    Parashar Ramanuj · 2013 · PubMed Central
  10. Şizofreni Tanılı Hastalarda Prolaktini Yükselten ve Az Etkileyen Antipsikotiklerin Prolaktin Seviyesi ve Kemik Mineral Yoğunluğu Üzerine Etkileri
    Süheyla Doğan Bulut, Serdar BULUT, Verda Tüzer, Mehmet Ak, Emine Ak, Cebrail Kısa, Çiğdem Aydemir, Erol Göka · 2014 · Nöro Psikiyatri Arşivi
  11. Risperidone long-acting injection as monotherapy and adjunctive therapy in the maintenance treatment of bipolar I disorder
    Andrea M. Fagiolini, Francesco Casamassima, W. Mostacciuolo, Rocco Nicola Forgione, Arianna Goracci, Benjamin I. Goldstein · 2010 · Expert Opinion on Pharmacotherapy
  12. Effect of age and disease on bone mass in Japanese patients with schizophrenia
    Norio Sugawara, Norio Yasui‐Furukori, Takashi Umeda, Shoko Tsuchimine, Akira Fujii, Yasushi Sato, Manabu Saito, Hanako Furukori, Kazuma Danjo, Masashi Matsuzaka et al. · 2012 · Annals of General Psychiatry
  13. CORRELATION BETWEEN PROLACTIN AND SYMPTOM PROFILE IN ACUTE ADMITTED WOMEN WITH RECURRENT SCHIZOPHRENIA
    Miroslav Herceg, Krešimir Puljić, Andrea Jambrošić Sakoman, Jelena Sušac, Ivana Todorić Laidlaw, Dora Herceg, Mirna Sisek-Šprem · 2020 · Psychiatria Danubina
  14. Prospective analysis of serum prolactin levels, clinical symptomatology and sexual functions in patients with schizophrenia switched to paliperidone palmitate 3‐monthly from paliperidone palmitate 1‐monthly: Preliminary findings of the first 3 months
    Ersin Hatice Karslıoğlu, Zeynep Kolcu, Nisa İrem Karslioğlu, Ali Çayköylü · 2021 · Human Psychopharmacology Clinical and Experimental
  15. Ostéopathies médicamenteuses (hors cortisone)
    Karine Briot · 2006 · La Presse Médicale
  16. Chronic risperidone exposure does not show any evidence of bone mass deterioration in animal model of schizophrenia
    Nataša Petronijević, Jelena P. Sopta, Mirjana Doknić, Nevena V. Radonjić, Milan Petronijević, Sandra Pekić, Nadja P. Marić, Miroslava Jašović‐Gašić, Vera M. POPOVIC · 2013 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  17. Changes in biomarkers of bone turnover in an aripiprazole add-on or switching study
    Rohit Jaibhagwan Lodhi, Salaj Masand, Amna Malik, Kuppuswami Shivakumar, Victoria McAllister, Veronica O’Keane, Leah C. Young, Adrian Hugh Heald, Roy A Sherwood, Katherine Jean Aitchison · 2016 · Schizophrenia Research
  18. High prevalence of risk factors for physical illness in a long-stay psychiatric unit
    Sinéad O’Brien, Enda Devitt, Mohamed Rifaat Ahmed, Colm McDonald · 2007 · Irish Journal of Psychological Medicine
  19. Comparison of whole body bone mineral density measurements between dual energy X-ray absorptiometry and novel bioelectrical impedance analysis
    Chih-Lin Chuang, Chung-Liang Lai, Ai-Chun Huang, Po-Hua Su, Lee-Ping Chu, Kuen-Chang Hsieh, Hsueh-Kuan Lu · 2024 · Scientific Reports
  20. Adverse Side Effects in Horses Following the Administration of Fluphenazine Decanoate
    John D. Baird, George A. Maylin · 2011
  21. The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study
    Norio Yasui‐Furukori, Kojiro Hashimoto, Norio Sugawara, Masamichi Ishioka, Kazuhiko Nakamura · 2014 · Neuropsychiatric Disease and Treatment
  22. Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients
    Norio Yasui‐Furukori, Hanako Furukori, Norio Sugawara, Shoko Tsuchimine, Akira Fujii, Yoshimasa Inoue, Sunao Kaneko · 2010 · Human Psychopharmacology Clinical and Experimental
  23. Acute effects of haloperidol, amisulpride, and quetiapine on bone turnover markers in patients with schizophrenia
    Liang, Ying, Su, Yun-Ai, Zhao, Zhen-Guo, Gao, Nan, Huang, Ji-Zhong, Tang, Mao-Qin, Li, Ke-Qing, Yang, Fu-De, Yu, Xin, Si, Tian-Mei · 2015 · Journal of Clinical Psychopharmacology
  24. Recommendations for the medical work‐up of first episode psychosis, including specific relevance to Indigenous Australians: A narrative review
    Kiernan Dorney, Michael Murphy · 2020 · Early Intervention in Psychiatry
  25. Antipsychotics Induced Reproductive Toxicity by Stimulating Oxidative Stress: A Comparative in Vivo and in Silico Study
    Büşra Dinçer, Ahmet Bülent Yazıcı, İrfan Çınar, Erdem Toktay, Jale Selli, Elif Çadırcı, Zafer Bayraktutan, Esra Yazıcı · 2023 · Chemistry & Biodiversity
  26. Schizophrenia and Gender
    Iñaki Zorrilla, Saioa López-Zurbano, Ana Isabel Cano, Ana María González-Pinto · 2014 · Springer eBooks
  27. Dance/movement therapy for improving balance ability and bone mineral density in long-term patients with schizophrenia: a randomized controlled trial
    Hengyong Guan, Zhaoxia Zhou, Xipo Li, Yanfen Pan, Zou Zhenmin, Xiangfei Meng, Kunya Guan, Lie Zhang, Zhanmin Li, Xueling Li et al. · 2023 · Schizophrenia
  28. Antipsychotic medication use and fracture: a case–control study
    Behnaz Azimi Manavi, Amanda L. Stuart, Julie Anne Pasco, Jason M. Hodge, D. Kavindi Weerasinghe, Rasika M. Samarasinghe, Lana J. Williams · 2023 · Scientific Reports
  29. Reproductive Health Among Those with Schizophrenia Spectrum Disorders: An Overview of Considerations Related to the Premenopausal Period, Pregnancy and Postpartum, and the Menopausal Transition, with a Focus on Recent Findings
    Lucy C. Barker, Simone Natalie Vigod · 2023 · Current Psychiatry Reports
  30. Managing Psychotic Illness in Young People: A Practical Overview
    Paul Alexander Tiffin · 2006 · Child and Adolescent Mental Health
  31. Beyond Reproduction: Pituitary Hormone Actions on Bone
    Tony Yuen, L. Sun, P. Liu, Harry C. Blair, M. New, Alberta Zambonin Zallone, Mone Zaidi · 2016 · Progress in molecular biology and translational science
  32. Hormones and Schizophrenia
    Jayashri Kulkarni, Emmy Gavrilidis, Roisin Worsley · 2015 · Handbook of behavioral neuroscience
  33. Rationale for a non-inferiority clinical trial design focused on subpopulations
    Pandurang M. Kulkarni, Eric S. Meadows, Sanjeev Ahuja, David Muram · 2004 · Current Medical Research and Opinion
  34. The Association Between Antipsychotics and Bone Fragility: An Updated Comprehensive Review
    Michele Mercurio, Giovanna Spina, Olimpio Galasso, Giorgio Gasparini, Cristina Segura‐Garcìa, Pasquale De Fazio, Renato de Filippis · 2024 · Diagnostics
  35. Women and psychosis: a guide to evidence-based, hormone-informed care
    Bodyl A. Brand, Sophie Behrman, Katie F. M. Marwick, Thomas James Reilly, Iris E. Sommer, Vikram Sinai Talaulikar, Robert Ali McCutcheon · 2026 · The Lancet Psychiatry
  36. Association between gonadal hormones and osteoporosis in schizophrenia patients undergoing risperidone monotherapy: a cross-sectional study
    Yi Chen, Yaoyao Zhang, Kaili Fan, Weiqian Xu, Chao Teng, Shuangshuang Wang, Wei Tang, Xiaomin Zhu · 2021 · PeerJ
  37. Bone Mineral Density as a Marker of Cumulative Estrogen Exposure in Psychotic Disorder: A 3 Year Follow-Up Study
    Christine van der Leeuw, Sanne C. T. Peeters, Patrick A.E. Domen, Marinus J.P.G. van Kroonenburgh, Jim van Os, Machteld C. Marcelis, Genetic Risk and Outcome in Psychosis (G.R.O.U.P.) · 2015 · PLoS ONE
  38. Clinical Pharmacology and Medication-Associated Side Effects: A Review of Second-Generation Antipsychotics for Schizophrenia
    Robert R. Conley, Deanna L. Kelly · 2007 · Clinical Schizophrenia & Related Psychoses
  39. Evaluation of prolactin levels in male patients with first-episode schizophrenia and its correlation with psychopathology
    Mohamed El Sayed El Taweel, Ahmed Mohamed Abdalla · 2017 · Middle East Current Psychiatry
  40. Prolactin monitoring in the acute psychiatry setting
    Benjamin Ian Perry, Katie J. Goldring, Sharmila J. Menon · 2015 · Psychiatry Research
  41. Risperidone accelerates bone loss in rats with autistic-like deficits induced by maternal lipopolysaccharides exposure
    Abdollah Amini, Zahra Namvarpour, Mozhdeh Namvarpour, Amir Raoofi · 2020 · Life Sciences
  42. Care for Women with Delusional Disorder: Towards a Specialized Approach
    Alexandre González-Rodríguez, Mary V. Seeman, Aida Álvarez Pedrero, A. Guàrdia, Nàdia Sanz, G.F. Fucho, Diego José Palao, Javier Labad · 2021 · Women
  43. Antipsychotika und Hyperprolaktinämie: Pathophysiologie, klinische Bedeutung, Abklärung und Therapie
    Anita Riecher‐Rössler, Christoph Schmid, Stefan Bleuer, M. Birkhäuser · 2009 · Gynäkologische Endokrinologie
  44. Comment on Hyperprolactinaemia and antipsychotic therapy in schizophrenia
    Oliver David Howes, Shubulade M Smith, Katherine Jean Aitchison · 2004 · Current Medical Research and Opinion
  45. Olanzapine decreased osteocyte maturation and Wnt/β-catenin signaling during loading of the alveolar bone in rats
    Saranda Disha-Ibrahimi, Borut Furlani, Gorazd Drevenšek, Samo Hudoklin, Janja Marc, Irena Prodan Žitnik, Jakob Sajovic, Martina Drevenšek · 2022 · Biomolecules and Biomedicine
  46. Thermoneutral housing does not rescue olanzapine-induced trabecular bone loss in C57BL/6J female mice
    Audrie L. Langlais, Rebecca V. Mountain, Roni F. Kunst, Deborah J. Barlow, Karen L. Houseknecht, Katherine J. Motyl · 2023 · Biochimie
  47. Bone mineral density and general health of long-term residential psychiatric inpatients
    Brian P. Hallahan, Declan Lyons, Patrick Doyle · 2008 · Irish Journal of Psychological Medicine
  48. Association between Anti-Psychotic Drugs Use and Hip Fractures in Patients with Dementia: A Nationwide Population-Based Study
    Chia-Hung Tang, Yi-Chen Lai, Yi‐Chen Chen, Shun-Min Chang, Yuhan Chen, Jung‐Yu Liao, Yi‐Chi Wang, Chung‐Han Ho, Ping‐Jen Chen · 2021 · International Journal of Environmental Research and Public Health
  49. The Importance of Screening for Osteoporosis in Mental Health Settings
    Marilyn M. Miller · 2009 · Clinical Schizophrenia & Related Psychoses
  50. Study of menstrual irregularities in patients receiving antipsychotic medications
    Mukund Murke, Suhas Gajbhiye, A Amritwar, SmitaR Gautam · 2011 · Indian Journal of Psychiatry
  51. Adverse Effects of Antipsychotics
    Pierre Landry, Anne‐Marie Rousseau, Leila Skalli · 2010 · Wiley eBooks
  52. The Pituitary‐Bone Connection
    Mone Zaidi, Tony Yuen, Li Sun, Terry F. Davies, Alberta Zambonin Zallone, Harry C. Blair · 2013 · Primer on the metabolic bone diseases and disorders of mineral metabolism
  53. Psychopharmaka bei internistischen Erkrankungen
    Christian Lange‐Asschenfeldt · 2008 · Springer eBooks
  54. Hyperprolactinemia in a Patient with a Pituitary Adenoma Receiving Antipsychotic Drug Therapy
    Richard William Carroll, Polyxeni Christodoulou, Kevin Baynes, David A Kahn · 2012 · Journal of Psychiatric Practice
  55. Antipsychotika und Hyperprolaktinämie: Pathophysiologie, klinische Bedeutung, Abklärung und Therapie
    Anita Riecher‐Rössler, Christoph Schmid, Stefan Bleuer, Martin Birkhäuser · 2009 · Neuropsychiatrie
  56. Antipsychotic-induced hyperprolactinemia in children and adolescents with mainly autism spectrum disorders : prevalence, symptoms, clinical consequences and genetic risk factors
    Yvette Roke · 2013
  57. Bipolar disorder: a review of current U.S. Food and Drug Administration approved pharmacotherapy
    Aashal Shah, Preeti P. Yadav, Mayur A. Chaudhari, JAYANT RAI, Naresh D. Kantharia · 2015 · International Journal of Basic & Clinical Pharmacology
  58. Hiperprolactinemia y tratamiento antipsicótico. Manifestaciones clínicas y manejo
    Elena Rubio‐Abadal, Judith Usall · 2013 · Psiquiatría Biológica
  59. Osteoporosis secundaria a fármacos
    Meritxell Sallés, Saúl Mario Gelman · 2009 · Seminarios de la Fundación Española de Reumatología
  60. Evaluation of the link between chronic antipsychotic use and osteoporosis
    Rohini Downs, Monica L. Mathys · 2013 · Mental Health Clinician
  61. The endocrine impact of long term risperidone therapy in Asian Indian patients
    JP Russell Ravan, Naveen Thomas, Thomas Vizhalil Paul, Samuel Prasanna, Nihal Thomas, Deepa Ramaswamy · 2017 · Open Journal of Psychiatry & Allied Sciences
  62. Pituitary Hormone-Driven Mechanism for Skeletal Loss
    Tony Yuen, Li Sun, Wahid Abu‐Amer, Peng Liu, Terry F. Davies, Harry C. Blair, Maria I. New, Alberta Zambonin Zallone, Mone Zaidi · 2017 · Molecular and integrative toxicology
  63. Vitamin D Levels in Lebanese Patients with Schizophrenia: A Case-Control Study
    Jocelyne Azar · 2017 · Annals of Nutritional Disorders & Therapy
  64. Complications of neuroleptic hyperprolactinaemia
    Galina Elevna Mazo, Горобец Людмила Николаевна · 2018 · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
  65. Psychopharmaka bei internistischen Erkrankungen
    Christian Lange‐Asschenfeldt, Günter Karl Stalla · 2011 · Springer eBooks
  66. Psychological structure of alexithymic space in patients with cardiovascular diseases
    Elena Y. Brel, Nikolay A. Bokhan, Irina Ya. Stoyanova · 2018 · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
  67. Increased off-target binding of [18F]florbetaben in the skull of women with reduced skull density
    Noah Hipp, Kim Lea Young, Ivayla Ilieva Apostolova, Susanne Klutmann, Iris Hardewig, Norman Koglin, Jürgen Gallinat, Ralph Buchert · 2024 · Nuklearmedizin - NuclearMedicine
  68. Outcomes following hip fracture surgery in adults with schizophrenia in Ontario, Canada: A 10-year population-based retrospective cohort study
    Hina Ansari, Kinwah Fung, Angela M. Cheung, Susan Brenda Jaglal, Earl R. Bogoch, Paul A. Kurdyak · 2024 · General Hospital Psychiatry
  69. Medications for Mental Health Disorders and Impact on Bone
    Nigel L. Leslie-Allen, James M. Bolton, William Donald Leslie · 2024 · Springer eBooks
  70. Antipsychotics and prolactinemia: biological regulation and clinical aspects
    Walter Donato Milano, Michele De Rosa, Luca Milano, Giovanni Nolfe, Claudio Petrella · 2010 · Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology
  71. Aripiprazole for neuroleptic induced hyperprolactinaemia
    Venkata B. Kolli, Durga Prasad Bestha, Vishal Madaan, Seenaiah Byreddy · 2013 · Cochrane Database of Systematic Reviews
  72. O impacto dos agentes antipsicóticos na densidade mineral óssea de pacientes esquizofrênicos
    Lísia Rejane Guimarães, Carmen Lúcia Leitão-Azevedo, Martha Guerra Belmonte de Abreu, Clarissa Severino Gama, Maria Inês Rodrigues Lobato, Paulo Silva Belmonte-de-Abreu · 2006 · Revista de Psiquiatria do Rio Grande do Sul
  73. Cariprazine is a modern antipsychotic with a favorable neuroendocrine profile
    Igor Vladimirovich DOROVSKIKH, Tatyana A. Pavlova, Julia M. Scheidegger · 2020 · Pharmacy Formulas
  74. Assessment of Hyperprolactinemia in Drug Naive Patients with Depression
    Subhendu Datta, Arindam Sur, Rumi Gayen, Indranil Chakraborty · 2021 · National Journal of Laboratory Medicine
  75. Duration of the untreated period affects bone mineral density in psychiatric patients requiring long‐term hospitalization: A cross‐sectional study
    Itsuka Kaga, Hiroyoshi Iwata, Akihiro Tokushige, Takushiro Akata, Shinichiro Ueda · 2022 · Psychiatry and Clinical Neurosciences Reports
  76. Dynamics of mental state and prolactin levels in patients with chronic schizophrenia during aripiprazole therapy
    Горобец Людмила Николаевна, И. В. Доровских, А. В. Литвинов, Буланов Вадим Сергеевич, S. K. Gamdullaev, Tatiana A. Pavlova · 2023 · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
  77. Hiperprolactinemia y disfunción sexual en el primer episodio psicótico tratado con risperidona
    Álvaro Cavieres F. · 2008 · Revista chilena de neuro-psiquiatría
  78. Metabolic aspects of hyperprolactinaemia
    Anna Kostrzak, Krzysztof Katulski · 2012
  79. Body composition and energy expenditure in men with schizophrenia
    Jenny-Kay Sharpe · 2007 · Faculty of Health
  80. THU0383 Osteoporosis in Epilepsy and Multiple Sclerosis Patients.
    Maroua SLOUMA, H. Sahli, S. Rekik, E. Choeur, Nihel Meddeb, M. Elleuch, S. Sallami · 2013 · Annals of the Rheumatic Diseases
  81. CORRELATION BETWEEN PROLACTIN AND SYMPTOM PROFILE IN ACUTE ADMITTED WOMEN WITH RECURRENT SCHIZOPHRENIA
    Miroslav Herceg, Krešimir Puljić, Andrea Jambrošić Sakoman, Jelena Sušac, Ivana Todorić Laidlaw, Dora Herceg, Mirna Sisek-Šprem · 2020
  82. Antipsychotika
    Gerhard Gründer · 2008 · Springer eBooks
  83. Wpływ flufenazyny i risperidonu na przebudowę kości u szczurów owariektomizowanych
    Maria Pytlik, Justyna Fronczek-Sokół · 2012 · Annales Academiae Medicae Silesiensis
  84. Population-based studies on risk of fracture in patients with neurological disorders
    Sander Pouwels · 2014 · Utrecht University Repository (Utrecht University)
  85. Prolactin and Schizophrenia, an Evolving Relationship
    J. Chris, John Pendlebury · 2011 · InTech eBooks
  86. 6 Antipsychotic drugs
    Alfonso Carvajal, Luis H. Martín Arias, Natalia Jimeno Bulnes · 2007 · Side effects of drugs annual
  87. O impacto de um programa de atividade física no tratamento de jogadores patológicos
    Daniela Lopes Angelo · 2011 · Digital Library of Theses and Dissertations (Universidade de São Paulo)
  88. Bone Mineral Density and Body Composition Assessment In Individuals with Severe Mental Illness
    Jeremy Patterson, Ashley M. Hervey, Ashley R. Fryman, Barbara Andres · 2010 · Medicine & Science in Sports & Exercise
  89. The deprescribing of calcium supplements in a state operated developmental center: a 10-year longitudinal pilot study
    Lawrence J. Hoke, Adam Dilich · 2014 · International Journal of Developmental Disabilities
  90. Effect of Largactil on Physiology of Reproduction in Adult Male Rat
    Mehrdad Shariati · 2014
  91. PSYCHOTROPIC MEDICATION AND THE ENDOCRINE SYSTEM
    Liana Dehelean, P. Dehelean, Daniela Jitaru, C.C. Vasilian · 2010
  92. Pituitary Hormones and the Pathophysiology of Osteoporosis
    Manasi Agrawal, Shitij Arora, Graziana Colaianni, Li Sun, Jameel Z. Iqbal, Mone Zaidi · 2012 · Springer eBooks
  93. Effects of severe mental illness on bone mineral density and body composition
    Ashley M. Hervey · 2010 · Holmes Museum Of Anthropology (Wichita State University)
  94. Hyperprolactinemia in Antipsychotic Use
    Ravinderjit Singh, Gagan Deep Mall · 2012 · Psychiatric Annals
  95. Antipsikotiklere Bağli Hiperprolaktinemi Antipsychotic-induced Hyperprolactinemia
    Serdar Bulut · 2015
  96. Bone and Fat
    Francisco José Albuquerque de Paula, Ingrid Dick‐de‐Paula, Masanobu Kawai, Clifford james Rosen · 2013 · Elsevier eBooks
  97. Hiperprolactinemia y disfunción sexual en el primer episodio psicótico tratado con risperidona Hiperprolactinaemia and sexual disfunction in first psychotic episode treated with risperidone
    Fernanda Cavieres, Artículo De Investigación · 2008
  98. World Psychiatryis indexed in PubMed, Current Contents/Clinical Medicine, Current Contents/Social and Behavioral Sciences, Science Citation Index, and EMBASE Âñåìèðíàÿ Ïñèõèàòðè÷åñêàÿ Àññîöèàöèÿ (ÂÏÀ)
    Mario Maj, Èçáðàííûé Ïðåçèäåíò, Allan Tasman, Helen Herrman · 2011
  99. Schizophrenia and osteoporosis
    Tatjana Nikolić, Nataša Petronijević · 2018 · Medicinski podmladak
  100. Antipsychotic Induced Hyperprolactinemia in Schizophrenia Patients
    Süheyla Doğan Bulut, Serdar Bulut, Esra Alataş · 2014 · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry